Cells lytically infected with Epstein-Barr virus are detected and separable by immunoglobulins from EBV-seropositive individuals

Journal of Virological Methods

Volumn 137, Issue 1, 2006, Pages 103-114

  Bhaduri McIntosh, Sumita ^a   Miller, George ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Epstein Barr virus; Lytic cycle induction; Lytic reactivation; Sodium butyrate

Indexed keywords

BUTYRIC ACID; DNA METHYLTRANSFERASE INHIBITOR; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN;

ADOLESCENT; ADULT; ARTICLE; B LYMPHOCYTE; CELL CYCLE; CELL MANIPULATION; CLINICAL ARTICLE; CLINICAL OBSERVATION; CONTROLLED STUDY; CYTOLYSIS; ENVIRONMENTAL FACTOR; EPSTEIN BARR VIRUS; FLOW CYTOMETRY; GENE EXPRESSION; GENETICS; HERPES; HUMAN; HUMAN CELL; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION SENSITIVITY; KINETICS; MOLECULAR DYNAMICS; PATHOGENESIS; PHYSIOLOGY; POPULATION RESEARCH; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; SENSITIVITY ANALYSIS; SEPARATION TECHNIQUE; SERODIAGNOSIS; VIRUS IMMUNITY;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; BUTYRATES; CELL LINE; CELL LINE, TUMOR; CELL SEPARATION; DNA MODIFICATION METHYLASES; EPSTEIN-BARR VIRUS INFECTIONS; FLOW CYTOMETRY; HERPESVIRUS 4, HUMAN; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; IMMUNOGLOBULIN G; LYMPHOCYTES; VIRUS ACTIVATION; VIRUS LATENCY;

HUMAN HERPESVIRUS 4;

EID: 33746916100     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2006.06.006     Document Type: Article

References (37)

1. Adamson A.L., Darr D., Holley-Guthrie E., Johnson R.A., Mauser A., Swenson J., and Kenney S. Epstein-Barr virus immediate-early proteins BZLF1 and BRLF1 activate the ATF2 transcription factor by increasing the levels of phosphorylated p38 and c-Jun N-terminal kinases. J. Virol. 74 (2000) 1224-1233
2. Carbone A. AIDS-related non-Hodgkin's lymphomas: from pathology and molecular pathogenesis to treatment. Human Pathol. 33 (2002) 392-404
3. Countryman J., Jenson H., Seibl R., Wolf H., and Miller G. Polymorphic proteins encoded within BZLF1 of defective and standard Epstein-Barr viruses disrupt latency. J. Virol. 61 (1987) 3672-3679
4. Countryman J., and Miller G. Activation of expression of latent Epstein-Barr herpesvirus after gene transfer with a small cloned subfragment of heterogeneous viral DNA. Proc. Natl. Acad. Sci. U.S.A. 82 (1985) 4085-4089
5. Durda P.J., Sullivan M., Kieff E., Pearson G.R., and Rabin H. An enzyme-linked immunosorbent assay for the measurement of human IgA antibody responses to Epstein-Barr virus membrane antigen. Intervirology 36 (1993) 11-19
6. Feng W.H., Cohen J.I., Fischer S., Li L., Sneller M., Goldbach-Mansky R., Raab-Traub N., Delecluse H.J., and Kenney S.C. Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas. J. Natl. Cancer Inst. 96 (2004) 1691-1702
7. Feng W.H., Hong G., Delecluse H.J., and Kenney S.C. Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas. J. Virol. 78 (2004) 1893-1902
8. Geser A., de The G., Lenoir G., Day N.E., and Williams E.H. Final case reporting from the Ugandan prospective study of the relationship between EBV and Burkitt's lymphoma. Int. J. Cancer 29 (1982) 397-400
9. Gradoville L., Grogan E., Taylor N., and Miller G. Differences in the extent of activation of Epstein-Barr virus replicative gene expression among four nonproducer cell lines stably transformed by oriP/BZLF1 plasmids. Virology 178 (1990) 345-354
10. Gradoville L., Kwa D., El-Guindy A., and Miller G. Protein kinase C-independent activation of the Epstein-Barr virus lytic cycle. J. Virol. 76 (2002) 5612-5626
11. Hadar T., Rahima M., Kahan E., Sidi J., Rakowsky E., Sarov B., and Sarov I. Significance of specific Epstein-Barr virus IgA and elevated IgG antibodies to viral capsid antigens in nasopharyngeal carcinoma patients. J. Med. Virol. 20 (1986) 329-339
12. Heston L., Rabson M., Brown N., and Miller G. New Epstein-Barr virus variants from cellular subclones of P3J-HR-1 Burkitt lymphoma. Nature 295 (1982) 160-163
13. Hinuma Y., and Grace Jr. J.T. Cloning of immunoglobulin-producing human leukemic and lymphoma cells in long-term cultures. Proc. Soc. Exp. Biol. Med. 124 (1967) 107-111
14. Hong G.K., Gulley M.L., Feng W.H., Delecluse H.J., Holley-Guthrie E., and Kenney S.C. Epstein-Barr virus lytic infection contributes to lymphoproliferative disease in a SCID mouse model. J. Virol. 79 (2005) 13993-14003
15. Imbert-Marcille B.M., Coste-Burel M., Robillard N., Foucaud-Gamen J., Billaudel S., and Drouet E. Sequential use of paraformaldehyde and methanol as optimal conditions for the direct quantification of ZEBRA and rta antigens by flow cytometry. Clin. Diagn. Lab. Immunol. 7 (2000) 206-211
16. Klein G., Zeuthen J., Terasaki P., Billing R., Honig R., Jondal M., Westman A., and Clements G. Inducibility of the Epstein-Barr virus (EBV) cycle and surface marker properties of EBV-negative lymphoma lines and their in vitro EBV-converted sublines. Int. J. Cancer 18 (1976) 639-652
17. Kudoh A., Fujita M., Kiyono T., Kuzushima K., Sugaya Y., Izuta S., Nishiyama Y., and Tsurumi T. Reactivation of lytic replication from B cells latently infected with Epstein-Barr virus occurs with high S-phase cyclin-dependent kinase activity while inhibiting cellular DNA replication. J. Virol. 77 (2003) 851-861
18. Li J.S., Zhou B.S., Dutschman G.E., Grill S.P., Tan R.S., and Cheng Y.C. Association of Epstein-Barr virus early antigen diffuse component and virus-specified DNA polymerase activity. J. Virol. 61 (1987) 2947-2949
19. Liabeuf A., Nelson Jr. R.A., and Kourilsky F.M. The detection of the Epstein-Barr virus (EBV) nuclear antigen (EBNA) by anticomplement immunofluorescence. Immunoglobulin class of antibodies and role of complement. Int. J. Cancer 15 (1975) 533-546
20. Luka J., Kallin B., and Klein G. Induction of the Epstein-Barr virus (EBV) cycle in latently infected cells by n-butyrate. Virology 94 (1979) 228-231
21. Miller G., and Lipman M. Release of infectious Epstein-Barr virus by transformed marmoset leukocytes. Proc. Natl. Acad. Sci. U.S.A. 70 (1973) 190-194
22. Mueller N., Evans A., Harris N.L., Comstock G.W., Jellum E., Magnus K., Orentreich N., Polk B.F., and Vogelman J. Hodgkin's disease and Epstein-Barr virus. Altered antibody pattern before diagnosis. N. Engl. J. Med. 320 (1989) 689-695
23. Mueller N., Mohar A., Evans A., Harris N.L., Comstock G.W., Jellum E., Magnus K., Orentreich N., Polk B.F., and Vogelman J. Epstein-Barr virus antibody patterns preceding the diagnosis of non-Hodgkin's lymphoma. Int. J. Cancer 49 (1991) 387-393
24. Okano M., Thiele G.M., Davis J.R., Grierson H.L., and Purtilo D.T. Epstein-Barr virus and human diseases: recent advances in diagnosis. Clin. Microbiol. Rev. 1 (1988) 300-312
25. Pearson G.R., Vroman B., Chase B., Sculley T., Hummel M., and Kieff E. Identification of polypeptide components of the Epstein-Barr virus early antigen complex with monoclonal antibodies. J. Virol. 47 (1983) 193-201
26. Prang N.S., Hornef M.W., Jager M., Wagner H.J., Wolf H., and Schwarzmann F.M. Lytic replication of Epstein-Barr virus in the peripheral blood: analysis of viral gene expression in B lymphocytes during infectious mononucleosis and in the normal carrier state. Blood 89 (1997) 1665-1677
27. Prince S., Keating S., Fielding C., Brennan P., Floettmann E., and Rowe M. Latent membrane protein 1 inhibits Epstein-Barr virus lytic cycle induction and progress via different mechanisms. J. Virol. 77 (2003) 5000-5007
28. Ragoczy T., Heston L., and Miller G. The Epstein-Barr virus Rta protein activates lytic cycle genes and can disrupt latency in B lymphocytes. J. Virol. 72 (1998) 7978-7984
29. Reedman B.M., Hilgers J., Hilgers F., and Klein G. Immunofluorescence and anti-complement immunofluorescence absorption tests for quantitation of Epstein-Barr virus-associated antigens. Int. J. Cancer 15 (1975) 566-571
30. Ryan J.L., Fan H., Swinnen L.J., Schichman S.A., Raab-Traub N., Covington M., Elmore S., and Gulley M.L. Epstein-Barr Virus (EBV) DNA in plasma is not encapsidated in patients with EBV-related malignancies. Diagn. Mol. Pathol. 13 (2004) 61-68
31. Serio T.R., Angeloni A., Kolman J.L., Gradoville L., Sun R., Katz D.A., Van Grunsven W., Middeldorp J., and Miller G. Two 21-kilodalton components of the Epstein-Barr virus capsid antigen complex and their relationship to ZEBRA-associated protein p21 (ZAP21). J. Virol. 70 (1996) 8047-8054
32. Summers W.C., and Klein G. Inhibition of Epstein-Barr virus DNA synthesis and late gene expression by phosphonoacetic acid. J. Virol. 18 (1976) 151-155
33. Taylor N., Countryman J., Rooney C., Katz D., and Miller G. Expression of the BZLF1 latency-disrupting gene differs in standard and defective Epstein-Barr viruses. J. Virol. 63 (1989) 1721-1728
34. Wick M.J., Woronzoff-Dashkoff K.P., and McGlennen R.C. The molecular characterization of fatal infectious mononucleosis. Am. J. Clin. Pathol. 117 (2002) 582-588
35. Xu J., Ahmad A., Blagdon M., D'Addario M., Jones J.F., Dolcetti R., Vaccher E., Prasad U., and Menezes J. The Epstein-Barr virus (EBV) major envelope glycoprotein gp350/220-specific antibody reactivities in the sera of patients with different EBV-associated diseases. Int. J. Cancer 79 (1998) 481-486
36. Yip T.T., Ngan R.K., Lau W.H., Poon Y.F., Joab I., Cochet C., and Cheng A.K. A possible prognostic role of immunoglobulin-G antibody against recombinant Epstein-Barr virus BZLF-1 transactivator protein ZEBRA in patients with nasopharyngeal carcinoma. Cancer 74 (1994) 2414-2424
37. Young L.S., Lau R., Rowe M., Niedobitek G., Packham G., Shanahan F., Rowe D.T., Greenspan D., Greenspan J.S., Rickinson A.B., et al. Differentiation-associated expression of the Epstein-Barr virus BZLF1 transactivator protein in oral hairy leukoplakia. J. Virol. 65 (1991) 2868-2874